- CEO
- Kunio Yamada
- Full Time Employees
- 9,292
- Sector
- Consumer non-durables
- Industry
- Household/Personal care
- Address
- 1-8-1, Tatsumi-nishi Osaka OS Japan 544-8666
- IPO Date
- Oct 2, 1961
- Business
- Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide; its core offerings include eye care products such as eye drops, contact lens care solutions, and eyewash; skin care items comprising face washes, lotions, creams, lip balms, sunscreens, and functional cosmetics; internal medicines like digestive aids and herbal remedies; over-the-counter pharmaceuticals encompassing ophthalmic, dermatological, gastrointestinal, and diagnostic drugs as well as Chinese herbal medicines and supplements; oral care products including toothpaste and mouthwashes; and additional services such as beauty counters for health consultations, diagnostic reagents, investment management, and contract development and manufacturing. The company operates primarily in the over-the-counter pharmaceuticals, consumer healthcare, and cosmetics segments, targeting consumers seeking health and beauty solutions, with a strong presence in Japan and international markets across Asia, North America, Europe, and beyond through subsidiaries and production facilities in the US, UK, China, Vietnam, Hong Kong, and Indonesia. Founded in 1899 as Shintendo Yamada Anmin Pharmacy and incorporated in 1949 with its current name, Rohto Pharmaceutical is headquartered in Ikuno-ku, Osaka, Japan, and lists on the Tokyo Stock Exchange Prime Market. Recent developments include the completion of its acquisition of Eu Yan Sang, a health and wellness platform, from Righteous Crane Holding in partnership with Mitsui in 2025 to bolster its natural health offerings; the acquisition of an additional 51% stake in Mono chem-pharm Produkte GmbH, an Austrian eye care firm, for 30 million euros in June 2024 to expand into Europe; and the purchase of Obagi trademark rights in Japan from Waldencast plc for $82.5 million in November 2025 to strengthen its skincare portfolio.